Malvern Instruments Viscotek SEC-MALS 20 Launch Goes Online
Recordings of Malvern Instruments’ July 25th launch of the Viscotek SEC-MALS 20 multiple angle light scattering (MALS) detector can now be viewed online. With this extension to its range of GPC/SEC detectors, Malvern becomes the only vendor to offer all types of static light scattering detector routinely used for absolute molecular weight measurement. The full launch webinar is available at www.malvern.com/secmals20launch and a 3-minute video that gives a basic introduction to the new system is available on YouTube at http://bit.ly/SEC-MALS20
Static light scattering is widely used within gel permeation/size exclusion chromatography (GPC/SEC) for the determination of the absolute molecular weight of protein, polymer and macromolecular species without the need for external, potentially inaccurate calibrations.
The new Viscotek SEC-MALS 20 offers numerous operational features that increase both accuracy and operational ease of use. Not only does it incorporate more detectors than any other commercial alternative, the increased detection at lower angles provides a significant improvement in accuracy compared with other MALS systems, even at high molecular weights. In addition, the new vertical, as opposed to lateral, sample flow cell with radial optics allows the use of a variety of mobile phase solvents, without the need for optical readjustment.
Malvern’s static light scattering detectors, which include low angle, right angle and multi angle detectors, are available individually and are compatible with any commercial GPC/SEC system, or may be supplied integrated within a multi detection Viscotek system for comprehensive polymer, protein, and macromolecule characterisation.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance